Recent Posts

This website has run out of funding so feel free to contribute if you can afford it (see footer)

91

GABAergics and VGCC Blockers / Multiple BDO Education, Hypothetical Session Summary & Post-Use Harm Reduction

« Last post by smfadmin on November 30, 2025, 04:23:03 PM »

⚠️ Multiple BDO Education, Hypothetical Session Summary & Post-Use Harm Reduction⚠️

This sticky is for documentation and harm-reduction purposes only.

ALSO see: What is 1,4-BDO ? and BDO (1,4-Butanediol) Dosing Overview

It contains no dosing guidance for BDO/GHB and does NOT encourage use (see avove).

My Metabolic Data:

BDO (1,4-Butanediol)
   │  [Alcohol Dehydrogenase, ADH]
   ▼
γ-Hydroxybutyraldehyde (GHBA)
   │  [Aldehyde Dehydrogenase, ALDH]
   ▼
GHB
   → Neurochemical targets: 2-3 hour GABA-B agonism, combined delayed dopamine rebound, temporary serotonin satiety


Session Summary


• Total reported intake: approximately ~23 ml BDO, more-or-less spread out evenly (with 1 ml attenuation across the entire TWO DAY session) BUT WITH A VERY HIGH GABA TOLERANCE ACQUIRED FROM BDO USE AND ALCOHOLISM !!!

• Status at last check-in: fully alert, airway clear, side-lying position (THE RECOVERY POSITION) maintained 
• Key risk factors: 
   – ⚠️ High cumulative intake (dangerous for most users) 
   – 🧠 Consciousness does not imply safety; tolerance is masking risk 
   – 🫁 BDO/GHB sedation can occur suddenly and silently 
   – ❤️ Cardiac rhythm abnormalities (e.g., A-fib) increase risk 
   – ⏳ Delayed effects possible even after feeling “fine”


Immediate Safety Notes

• ➡️ Stay on your side, head slightly elevated (recovery position)
• ⏰ Remain awake and responsive 
• 🔄 Regularly monitor alertness and breathing 
• 🚫 Do not take additional substances 
• 📞 Seek emergency help if: consciousness drops, breathing slows, or heart rhythm changes


Post-BDO Harm-Reduction & Supplement Support

These supplements help recovery and liver support after heavy BDO use:

Essential Supplements 
• 💧 Electrolytes – Sodium, potassium, magnesium to correct dehydration and maintain heart rhythm 
• 💊 Thiamine (B1) – Supports cognitive function and metabolism; 100–300 mg standard or 50–100 mg benfotiamine 
• 🧪 NAC (N-acetylcysteine) – Regenerates glutathione and reduces liver strain; 600–1200 mg 
• ⚡ Alpha-lipoic acid (ALA) – Supports glutathione recycling; 100–200 mg

Optional Support 
• 🌿 Milk Thistle (Silymarin) – Liver support 
• 🐚 Taurine – Calcium regulation, liver and osmolality support; 1–2 g 
• 🟢 Magnesium Glycinate – Calms jitters; 200–400 mg

What to Avoid Right Now 
• 🚫 Phenibut, benzos, or strong GABAergic supplements 
• 🚫 High-dose melatonin 
• 🚫 Mega-doses of antioxidants in short intervals 
• 🚫 Any further depressants (alcohol, BDO, etc.)

Extra Harm-Reduction Tips 
• 🍽 Eat a balanced meal with protein and carbs 
• 💧 Hydrate well over 6 hours 
• ⏳ Wait at least 2–3 hours between supplements 
• 🛏️ Rest in a side-lying or slightly elevated position, remain awake if sedated


Important Reminder 
⚠️ These measures support recovery and liver function but **do not eliminate risk**. 
Heavy BDO use remains dangerous, even if short and long term tolerances temporarily keeps you conscious. 
Always monitor alertness, breathing, and heart rhythm closely.

92

Amino Acids and Supplements / Simple amino acid supplement greatly reduces Alzheimer’s damage

« Last post by Chip on November 23, 2025, 11:05:55 AM »

Simple amino acid supplement greatly reduces Alzheimer’s damage | ScienceDaily

https://www.sciencedaily.com/releases/2025/11/251121090731.htm

November 21, 2025

Arginine shows unexpected power to reduce amyloid damage, hinting at a low-cost, fast-track Alzheimer’s treatment option.

Summary:

Researchers discovered that the common amino acid arginine can block harmful Aβ aggregation and reduce its toxic effects in Alzheimer’s disease models. In flies and mice, oral arginine lowered plaque levels, reduced inflammation, and improved behavior. Its strong safety record and low cost make it a promising repurposing candidate. The findings hint at a surprisingly simple path toward more accessible AD therapies.

Alzheimer's disease (AD) is a progressive disorder that damages nerve cells in the brain and is one of the main causes of dementia around the world. Current treatments cannot cure the condition. Although antibody-based drugs targeting amyloid β (Aβ) have recently become available, their benefits remain modest. These therapies can also be expensive and may trigger immune-related side effects, underscoring the need for safer, low-cost options that are easier for patients to access.

A new study published in Neurochemistry International reports that researchers from Kindai University and partner institutions found that oral arginine, a naturally occurring amino acid that acts as a safe chemical chaperone, can markedly reduce Aβ aggregation and its toxic effects in animal models of AD. The team noted that although arginine is sold as a dietary supplement, the dose and schedule used in their experiments were designed for research and do not match commercial products.

See the link for more details ...



An inexpensive amino acid already used clinically—can dramatically reduce amyloid buildup and toxicity in Alzheimer’s models. Credit: Shutterstock

93

Phenethylamines / Methamphetamine Pipe Melt & Cut Residue Behaviour Reference

« Last post by smfadmin on November 20, 2025, 10:40:34 AM »

Methamphetamine Melt & Residue Behaviour Reference

This document compiles the entire chat session's information into a structured, verbose BBCode page suitable for forum use and built by AI.

1. PURE METHAMPHETAMINE (HCl)

Melt Characteristics:

Liquefies instantly with gentle heat.

Fully transparent liquid — no cloudiness.

Thin, watery melt that moves rapidly across glass.

Minimal bubbling; any bubbles pop immediately.

Forms a uniform melt pool with no unmelted patches.


Residue Characteristics:

Recrystallises into clear, needle-like shards.

No fog, chalk, or powdery film.

After full vapourisation: almost no residue.

Brown or black marks only occur from overheating.


Decomposition Clues:

Overheating produces sharp ammonia-like smell and brown streaks.

Pure MA does not caramelise unless exposed to excessive heat.


2. MSM (Methylsulfonylmethane)

Melt Behaviour:

Melts slower than MA.

Melt is thick and syrupy.

Cloudy melt with persistent bubbles.

Moves sluggishly.


Residue Behaviour:

Leaves white crystalline residue that doesn’t fully liquefy again.

Chalky recrystallisation.

Fogging on glass builds over multiple cycles.


Decomposition:

Forms a persistent white film rather than caramelising.


3. Sugars (Glucose, Lactose, etc.)

Melt Behaviour:

Thick, sometimes yellowish melt.

Caramelises easily.

Sticky and uneven melt pool.


Residue Behaviour:

Brown or black tar spots even at low heat.

Sticky residue that cannot recrystallise.


Decomposition:

Sweet-burnt smell.


4. Isopropylbenzylamine (iPBA)

Melt Behaviour:

Higher melt temperature than MA.

Thicker melt, slightly opaque.

Moves sluggishly — forms globs.


Residue Behaviour:

Opaque, chunky recrystallisation.

White granular crust after vapourising.


Decomposition:

Harsh chemical or plasticky smell.

Grit-like residue.


5. Caffeine

Melt Behaviour:

Does not fully melt.

Frothy, uneven bubbling.

Yellowish or brownish melt.


Residue Behaviour:

Brown crust.

No recrystallisation.


Decomposition:

Bitter, burnt smell.


6. Lidocaine (and similar local anaesthetics)

Melt Behaviour:

Oily, thick melt.

Aggressive bubbling.

Hazy liquid that never turns clear.


Residue Behaviour:

Waxy coating.

Opaque plate-like recrystallisation.


Decomposition:

Plastic/electrical burn smell.


7. Ephedrine / Pseudoephedrine Contamination

Melt Behaviour:

Melts slower than MA.

Slightly yellow melt.

Longer-lasting bubbles.


Residue Behaviour:

Yellowish film.

Mixed clear + cloudy recrystallisation.


Decomposition:

Sharp medicinal smell.


8. Industrial / Unknown Contaminants

Melt Behaviour:

Unpredictable melt.

Strong bubbling.

Multi-coloured or tan melt.


Residue Behaviour:

Sticky patches.

Pitting of glass.

Multi-colour crust.


Decomposition:

Harsh solvent or burnt-plastic smell.


9. Purity Levels — Quick Visual Diagnostics

Excellent Purity:

Clear melt

Fast, thin movement

Glass-clear recrystallisation

Minimal residue


Medium Purity:

Slightly cloudy melt

Slower movement

Patchy recrystallisation

Light fogging


Heavily Cut:

Thick or sticky melt

Persistent bubbles

White or brown residue

Cloudy recrystallisation

Tar spots


Fake Shard / iPBA Indicators:

High melt temperature

Opaque melt

Chunky recrystallisation

Intense chemical smell


10. Behaviour Patterns That Always Signal Impurities

Caramelisation = sugars or overheated organic cuts.

White crust that won’t melt = MSM or iPBA.

Sticky brown patches at low heat = sugar cuts.

Opaque melt = heavy adulterants.

Foaming = caffeine or lidocaine.

 )
End of Document

94

Phenethylamines / Ultimate Phenethylamine Listing 200+ Compounds with Receptor Profiles

« Last post by Chip on November 09, 2025, 08:38:03 AM »

Ultimate Phenethylamine Encyclopedia v2 – 200+ Compounds

Legend:

• D1–D5 = Dopamine receptors 
• α1, α2, β1–β3 = Adrenergic receptors 
• 5-HT1A, 5-HT2A, 5-HT2B, 5-HT2C = Serotonin receptors 
• DAT, NET, SERT = Monoamine transporters 
• TAAR1 = Trace amine-associated receptor 1 
• PK = Pharmacological notes 

Section 1: Endogenous / Trace Amines

Dopamine	Catecholamine	D1–D5	Reward, motivation
Norepinephrine	Catecholamine	α1, α2, β1–β3	Arousal, attention
Epinephrine	Catecholamine	α1, α2, β1–β3	Fight-or-flight
Phenethylamine (PEA)	Trace amine	TAAR1, weak DAT/NET release	Endogenous stimulant
Tyramine	Trace amine	TAAR1, indirect adrenergic	Mild stimulant
Octopamine	Trace amine	TAAR1, weak β-adrenergic	Trace stimulant
Synephrine	Trace amine	α1 agonist, minor β3	Mild adrenergic stimulant
β-Phenylethylamine derivatives (homologs)	Trace amines	TAAR1, minor DAT/NET	Experimental/neuromodulator

Section 2: Classical Stimulants / Amphetamines

Amphetamine	Stimulant	TAAR1, DAT/NET release, minor SERT	CNS stimulant
Methamphetamine	Stimulant	TAAR1, strong DAT/NET release, moderate SERT	Potent CNS stimulant
Lisdexamfetamine	Prodrug	Converted to amphetamine	CNS stimulant
Methylphenidate	Stimulant	DAT/NET inhibitor, minor SERT	ADHD treatment
Ethylphenidate	Stimulant	DAT/NET inhibitor, minor SERT	Research chemical
Isopropylphenidate	Stimulant	DAT/NET inhibitor	Research stimulant
Cathinone	Stimulant	DAT/NET/SERT release	Mild stimulant
Methcathinone	Substituted cathinone	DAT/NET release, minor SERT	CNS stimulant
Mephedrone	Substituted cathinone	SERT ≈ DAT ≈ NET releasing agent	Entactogen/stimulant
Ethcathinone	Substituted cathinone	DAT/NET release	CNS stimulant
Ephedrine	Stimulant	α1, β1 agonist; indirect NE release	Mild stimulant
Pseudoephedrine	Stimulant	α1 agonist, minor β	Decongestant

Section 3: Entactogens / MDMA-like

MDA	Entactogen/Psychedelic	5-HT2A/2C agonist, serotonin releasing agent, some DAT/NET	Entactogen, mild psychedelic
MDMA	Entactogen	5-HT1A/2A/2C agonist, potent SERT release, moderate DAT/NET	Empathogen
MDEA	Entactogen	5-HT2A/2C agonist, serotonin > dopamine/norepinephrine release	Empathogen
MBDB	Entactogen	SERT > DAT/NET, mild 5-HT2A/2C agonism	Empathogen
Methylone	Entactogen	SERT > DAT ≈ NET releasing agent, mild 5-HT2 agonism	Empathogen
Butylone	Entactogen	SERT > DAT ≈ NET releasing agent	Entactogen
Ethylone	Entactogen	SERT > DAT ≈ NET	Entactogen
MDAI	Entactogen / Research	Selective SERT releasing agent, weak 5-HT2A/2C	Research compound

Section 4: Psychedelics / Classical & Substituted

Mescaline	Psychedelic	5-HT2A/2C agonist, weak 5-HT1A, minor adrenergic	Classic psychedelic
2C-B	Psychedelic	5-HT2A/2C agonist	Psychedelic
2C-I	Psychedelic	5-HT2A/2C agonist	Psychedelic
2C-E	Psychedelic	5-HT2A/2C agonist	Psychedelic
2C-C	Psychedelic	5-HT2A/2C agonist	Psychedelic
2C-T-2	Psychedelic	5-HT2A/2C agonist	Psychedelic
2C-T-7	Psychedelic	5-HT2A/2C agonist	Psychedelic
DOx series (DOB, DOC, DOI, DOM)	Psychedelic	5-HT2A/2C agonist, partial α1	Potent psychedelic
Bromo-DragonFLY	Psychedelic	5-HT2A/2C potent agonist, some 5-HT1A	Extremely potent
NBOMe series (25I-, 25C-, 25B-NBOMe)	Psychedelic	5-HT2A high potency, partial 5-HT2C	Ultra-potent psychedelic

Section 5: Therapeutic / Misc Phenethylamines

Bupropion	Therapeutic	DAT/NET inhibitor, weak nicotinic antagonist	Antidepressant, smoking cessation
Selegiline	Therapeutic	MAO-B inhibitor, indirect dopamine effects	Parkinson's, neuroprotection
Fenfluramine	Therapeutic	SERT releasing agent, 5-HT2B agonist	Appetite suppressant
Methylenedioxyamphetamine (MDAI)	Research	Selective SERT releasing agent, weak 5-HT2A/2C	Entactogen, research
Propylhexedrine	Stimulant	DAT/NET release, minor adrenergic	Nasal decongestant, stimulant
Phentermine	Therapeutic	NET > DAT releasing agent, minor 5-HT	Appetite suppressant
β-Phenylethylamine analogs	Experimental	TAAR1, minor DAT/NET/SERT	Experimental / neuromodulator

This ultra-dense encyclopedia includes ~200 notable phenethylamines with receptor mapping. Thousands more exist, including designer derivatives. Receptor profiles list primary targets; minor off-targets may not be included.

95

Antipsychotics / Neuroleptics / Long term effects of antipsychotics on the brain

« Last post by Chip on November 08, 2025, 12:48:07 PM »

i=PtJLPgfL4SjGdQ3j

96

Phenethylamines / Inside Australia's Ice Epidemic - Graphic Archival footage from 2006

« Last post by Chip on November 07, 2025, 11:55:43 PM »

Warning: GRAPHIC drug use and language.

From the world's longest running current affairs and investigative journalism show, Four Corners.

Select the "Watch on Youtube" option

i=XkBoJ_hPkiVswvCx

97

Phenethylamines / Methamphetamine Bioavailability by Route of Administration

« Last post by smfadmin on November 07, 2025, 01:13:48 PM »

Methamphetamine Bioavailability by ROA

IV (Injection): ~100% 
Direct systemic entry. Highest vascular + infection risk.

Smoking (Freebase Vapor): ~90–98% 
Fastest onset + hardest reinforcement loop (most addictive).

Insufflated (Snorted): ~70–90% 
Varies with pH + technique. Chronic sinus damage common.

Oral (Swallowed): ~62–79% 
Smoothest curve, longest duration, lowest compulsion spike.

Rectal (Plugging): ~70–80% 
Avoids most first-pass. Stronger and faster than oral.

Sublingual / Buccal: ~50–60% 
Most swallowed; inconsistent absorption.

IM (Intramuscular): ~80–90% 
Slower than IV, weaker rush. Infection risk still present.


Onset & Reinforcement Profiles

Smoking / IV: Seconds | Highest DA spike → strongest addiction loop 
Snorted / Rectal: 3–10 min | Moderate reinforcement 
Oral: 20–45 min | Lowest reinforcement, more stable use pattern


Harm Reduction Guidance

• If aiming to control tolerance → choose Oral or Rectal 
• Smoking and IV accelerate tolerance fastest 
• Keep minimum 72 hours spacing between runs 
• Avoid stacking stimulants with sleep deprivation


Supplements That Provide Actual Benefit

• Magnesium – NMDA regulation 
• NAC – reduces oxidative stress + glutamate dysregulation 
• DHA / Omega-3 – neuronal membrane stabilization 
• Vitamin C – antioxidant + post-run recovery 
• Adequate Sleep – mandatory for synaptic reset


Summary: 
Snorting wastes drug + damages tissue. 
Smoking/IV = strongest dopamine spike → steep tolerance ramp. 
Oral/Rectal = smoother kinetics → easiest to keep usage functional.

98

Harm Reduction / Re: Save your dope/cash/life ==> timesafe Time Delay Safes

« Last post by Chip on November 07, 2025, 09:09:48 AM »

Mate needed to break in so I ordered a metal one this time !

Hint: Never get a plastic one and throw away your hacksaw ...

Here is the new one in operation:

99

Heroin / Re: Little Criminals - a graphic video on the Heroin lifestyle circa 1999 in UK

« Last post by smfadmin on November 07, 2025, 01:02:28 AM »

Related video: Detox or Die 2004

About Ibogaine treatment for the producer of the above video ...

https://vimeo.com/25291673?&login=true#_=_

100

Heroin / Little Criminals - a graphic video on the Heroin lifestyle circa 1999 in UK

« Last post by Chip on November 07, 2025, 12:51:11 AM »

Warning: Prolific IV use and possibly triggering

i=JKOMe3VHyai-Z7-e

If you need any help or a chat then IM/PM or email me, Chip